Instructions for use FEMOSTON® 2/10 (FEMOSTON® 2/10)

Release form and composition

Femoston 1/10 is available in the form of film-coated tablets: round, biconvex, engraved “379” on one side, white tablet core with a rough structure; in one blister there are two types of tablets - white and gray (28 tablets in a blister - 14 pieces of white and gray; in a cardboard pack there are 1, 3 or 10 blisters).

Content of active ingredients in 1 tablet:

• white tablet: estradiol hemihydrate – 1.03 mg, which is equivalent to the content of 1 mg estradiol;
• gray tablet: estradiol hemihydrate – 1.03 mg, which is equivalent to the content of 1 mg estradiol; dydrogesterone – 10 mg.

Auxiliary components: lactose monohydrate, hypromellose, starch, colloidal silicon dioxide, magnesium stearate.

Shell composition:

• white tablet: opadry Y-1-7000 white [macrogol 400, titanium dioxide (E171), hypromellose];
• gray tablet: opadry II 85F27664 gray [macrogol 3350, polyvinyl alcohol, titanium dioxide (E171), iron (II) oxide black (E172), talc].

Femoston

Active substance:

Dydrogesterone*, Estradiol* (Dydrogesterone, Estradiol*)

Pharmgroup:

Estrogens, gestagens; their homologs and antagonists in combinations

Average price in pharmacies

Pharmacological properties

Pharmacodynamics

Femoston 1/10 is a combination drug intended for hormone replacement therapy (HRT) to prevent bone loss in the postmenopausal period and after oophorectomy. The identity of estradiol hemihydrate to endogenous human estradiol, which is the most active estrogen, makes it possible to compensate for the deficiency of estrogen in the body of a woman at menopausal age and reduces the symptoms of menopause during the first weeks of using the drug. The therapeutic effectiveness of dydrogesterone (progestogen) is similar in activity to the action of progesterone for parenteral administration. Dydrogesterone during HRT ensures complete secretory transformation of the endometrium. Its presence in the drug reduces the risk of developing endometrial hyperplasia, which is increased by the action of estrogens.

Pharmacokinetics

After taking Femoston 1/10 orally, micronized estradiol and dydrogesterone are rapidly and completely absorbed from the gastrointestinal tract. The bioavailability of dydrogesterone is 28%, the maximum concentration in the blood plasma occurs after 0.5–2.5 hours.

Binding to blood plasma proteins: estradiol - approximately 98-99% (with albumin - 30-52%, with globulin - up to 69%), dydrogesterone - more than 90% of the dose taken.

In the liver, estradiol is metabolized to estrone and estrone sulfate, which have estrogenic activity. Estrone sulfate also has the ability of enterohepatic recirculation.

Dydrogesterone is completely metabolized, its main metabolite is 20-a-dihydrodydrogesterone (DHD), the maximum concentration in the blood plasma is reached approximately 1.5 hours after taking Femoston 1/10. The plasma concentration of DHD significantly exceeds the initial level of dydrogesterone concentration.

The lack of estrogenic and androgenic activity is determined by the characteristic feature of all dydrogesterone metabolites to retain the 4,6-dien-3-one configuration of the original substance and the absence of 17alpha-hydroxylation.

The half-life for dydrogesterone is 5–7 hours (DGD is 14–17 hours), estrone and estradiol is 10–16 hours.

Estrogens pass into breast milk.

Estrone and estradiol in a state conjugated with glucuronic acid are excreted primarily through the kidneys.

Approximately 63% of the dose of dydrogesterone is excreted by the kidneys; its complete elimination occurs only after 72 hours. Its total plasma clearance is 6.4 l/min. DHD is detected in urine primarily as a glucuronic acid conjugate.

With daily intake of Femoston 1/10, the equilibrium concentration of estradiol occurs after 5 days, dydrogesterone - after 3 days.

The pharmacokinetic properties of dydrogesterone and DHD do not change with repeated administration.

Contraindications

Absolute:

• bleeding from the vagina of unknown etiology;
• breast cancer, including suspected;
• endometrial cancer and other estrogen-dependent malignant neoplasms, including if they are suspected;
• meningioma and other progestogen-dependent neoplasms, including if they are suspected;
• untreated endometrial hyperplasia;
• arterial and venous thrombosis, including deep vein thrombosis (including medical history);
• thromboembolism, including hemorrhagic or ischemic cerebrovascular disorders, pulmonary embolism, myocardial infarction (including medical history);
• pronounced or multiple risk factors for the development of venous or arterial thrombosis in patients with an acquired or hereditary predisposition, such as angina pectoris, cerebrovascular disease, transient ischemic attacks, atrial fibrillation, coronary artery disease, complicated lesions of the heart valve apparatus, antithrombin III deficiency, the presence of antibodies to phospholipids (lupus anticoagulant, antibodies to cardiolipin), protein C or S deficiency, prolonged immobilization, severe obesity (body weight index more than 30 kg per 1 m2);
• malignant liver tumors;
• acute or chronic liver disease (including medical history);
• porphyria;
• lactase deficiency, galactose intolerance, glucose-galactose malabsorption syndrome;
• pregnancy period;
• breast-feeding;
• hypersensitivity to the components of the drug.

It is recommended to be careful when prescribing Femoston 1/10 as HRT if you have or have a history of the following diseases and conditions: arterial hypertension, endometriosis, uterine leiomyoma, the presence of risk factors for the occurrence of estrogen-dependent tumors (including first-degree relatives with breast cancer) , bronchial asthma, diabetes mellitus (with and without vascular complications), benign liver tumors, cholelithiasis, severe headache, migraine, systemic lupus erythematosus, epilepsy, otosclerosis, history of endometrial hyperplasia.

Immediate discontinuation of Femoston 1/10 is required if liver dysfunction, jaundice, uncontrolled arterial hypertension, or migraine-like headaches appear during treatment.

Instructions for use of Femoston 1/10: method and dosage

Femoston 1/10 tablets are taken orally, regardless of meals, at a time convenient for the woman, but always at the same time of day.

Recommended dosage: 1 pc. 1 per day. The package is designed for 28 days; you should start taking tablets from the blister with white tablets (marked with the number 1), which contain 1 mg of estradiol. After 14 days, therapy is continued with gray tablets (marked with the number 2 in the blister), they contain 1 mg of estradiol and 10 mg of dydrogesterone. After finishing taking the tablets from the current blister, therapy is continued by taking white tablets from the new package. HRT involves regular, continuous use of the drug.

If you accidentally miss taking the next dose of Femoston 1/10, the tablet should be taken as soon as you remember, if the period of delay does not exceed 12 hours (the period from taking the previous dose to 36 hours). If the delay is more than 12 hours, then the missed tablet should not be taken, and the next day take the usual dose at the prescribed time. If you miss the next dose of the drug, the risk of spotting or breakthrough uterine bleeding increases.

When switching from the use of another hormonal drug (cyclic or continuous sequential regimen), you must end the current cycle and start taking Femoston 1/10. When switching from a continuous combination therapy regimen, you can start treatment with Femoston 1/10 on any day.

If the clinical effectiveness of the drug is insufficient due to estrogen deficiency, the dosage can be adjusted by prescribing Femoston 2/10.

Price

The cost of the medicine starts from 900 rubles. per package and depends on the dosage of the active substance and the region of distribution.

Femoston is a popular antimenopausal drug that can be used for women at different stages of menopause. Reviews from patients who have taken an effective drug can be positive or negative, depending on the characteristics of the body and the nuances of use. When taken correctly and following the recommendations, the tablets do not cause complications.

Side effects

• from the reproductive system and mammary glands: very often - tension or soreness of the mammary glands; often - metrorrhagia, impaired vaginal secretion, minor bleeding in postmenopause, pain in the lower abdomen, heavy menstrual-like bleeding, acyclic bleeding, absence or scant menstrual bleeding, painful menstrual-like bleeding, vaginal candidiasis; uncommon – enlarged mammary glands, increased size of leiomyoma, premenstrual-like syndrome;
• from the nervous system: very often – headache; often – dizziness, migraine;
• from the cardiovascular system: infrequently - increased blood pressure, venous thromboembolism; rarely - myocardial infarction;
• mental disorders: often – nervousness, depression; infrequently – libido disturbance;
• from the gastrointestinal tract: very often – abdominal pain; often – flatulence, nausea, vomiting;
• from the hepatobiliary system: infrequently - impaired liver function, including in combination with abdominal pain, jaundice, malaise, asthenia; gallbladder pathology;
• from the skeletal muscles and connective tissue: very often – back pain (lumbar pain);
• on the part of the immune system: infrequently – hypersensitivity to the components of the drug;
• dermatological reactions: often - allergic reactions, including urticaria, skin rash, itching; rarely – angioedema, vascular purpura;
• general disorders: often - peripheral edema, asthenic conditions (malaise, weakness, fatigue);
• infectious diseases: infrequently – cystitis;
• other reactions: often - increase in body weight; infrequently – loss of body weight.

In addition, during combination therapy with estrogen and progestogen (including estradiol and dydrogesterone), the following undesirable effects may develop:

• from the body as a whole: neoplasms of benign, malignant and unspecified etiology (including ovarian cancer, endometrial cancer, meningioma);
• from the cardiovascular system: arterial thromboembolism;
• from the hematopoietic system: hemolytic anemia;
• from the nervous system: provoking attacks of epilepsy, chorea, risk of developing dementia against the background of hormone replacement therapy started over the age of 65 years;
• from the immune system: systemic lupus erythematosus;
• from the reproductive system and mammary glands: cervical erosion, fibrocystic mastopathy;
• from the organs of vision: increased curvature of the cornea, intolerance to contact lenses;
• from the skeletal muscles and connective tissue: cramps in the muscles of the lower extremities;
• from the genitourinary system: urinary incontinence;
• from the side of metabolism: hypertriglyceridemia;
• from the gastrointestinal tract: with hypertriglyceridemia - pancreatitis;
• diagnostic studies: increased levels of thyroid hormones;
• dermatological reactions: erythema nodosum, erythema multiforme, chloasma and/or melasma;
• other reactions: with porphyria – worsening of the disease.

Instructions:

Clinical and pharmacological group

23.042 (Anti-climacteric drug)

Release form, composition and packaging

Film-coated tablets are available in two types.

White film-coated tablets, round, biconvex, embossed with “S” above the “∇” symbol on one side and “379” on the other (14 pcs. per blister).

Excipients: lactose monohydrate, hypromellose, corn starch, colloidal silicon dioxide, magnesium stearate.

Shell composition: Opadry OY-1-7000 white.

Gray film-coated tablets, round, biconvex, embossed with an “S” above the “∇” symbol on one side and “379” on the other; white tablet core (14 pieces in a blister).

Excipients: lactose monohydrate, hypromellose, corn starch, colloidal silicon dioxide, magnesium stearate.

Shell composition: Opadry OY-8243 grey.

28 pcs. - blisters (1) - cardboard packs. 28 pcs. - blisters (3) - cardboard packs. 28 pcs. - blisters (10) - cardboard packs.

Film-coated tablets are available in two types.

Pink, round, biconvex, film-coated tablets, embossed with an “S” above the “∇” on one side and “379” on the other side; white tablet core (14 pieces in a blister).

Excipients: lactose monohydrate, hypromellose, corn starch, colloidal silicon dioxide, magnesium stearate.

Shell composition: Opadry OY-6957 pink.

Light yellow, round, biconvex, film-coated tablets, embossed with an “S” above the “∇” symbol on one side and “379” on the other side; white tablet core (14 pieces in a blister).

Excipients: lactose monohydrate, hypromellose, corn starch, colloidal silicon dioxide, magnesium stearate.

Shell composition: Opadry OY-02B22764 yellow.

28 pcs. - blisters (1) - cardboard packs. 28 pcs. - blisters (3) - cardboard packs. 28 pcs. - blisters (10) - cardboard packs.

pharmachologic effect

A combined two-phase drug for hormone replacement therapy, containing micronized 17β-estradiol as an estrogenic component and dydrogesterone as a gestagenic component. Both components are analogues of female sex hormones (estradiol and progesterone).

Estradiol replenishes the deficiency of estrogen in the female body after menopause and provides effective relief of psycho-emotional and vegetative menopausal symptoms, such as hot flashes, increased sweating, sleep disturbances, increased nervous excitability, dizziness, headache, involution of the skin and mucous membranes, especially the genitourinary system (dryness) and irritation of the vaginal mucosa, pain during sexual intercourse).

Hormone replacement therapy (HRT) with Femoston® prevents bone loss in the postmenopausal period caused by estrogen deficiency.

Taking Femoston® leads to a change in the lipid profile towards a decrease in the level of total cholesterol and LDL and an increase in HDL.

Dydrogesterone is a gestagen, effective when taken orally, which completely ensures the onset of the secretion phase in the endometrium, thereby reducing the risk of developing endometrial hyperplasia and/or carcinogenesis (increased with the use of estrogens). Dydrogesterone does not have estrogenic, androgenic, anabolic or glucocorticoid activity.

Pharmacokinetics

Estradiol

Suction

After taking the drug orally, micronized estradiol is easily absorbed.

Metabolism and excretion

Estradiol is metabolized in the liver to form estrone and estrone sulfate. Estrone sulfate undergoes intrahepatic metabolism.

Glucuronides of estrone and estradiol are excreted primarily in the urine.

Dydrogesterone

Suction

In the human body, dydrogesterone is rapidly absorbed from the gastrointestinal tract.

Metabolism

Metabolized completely. The main metabolite of dydrogesterone is 20-dihydrodydrogesterone, present in urine mainly as a glucuronic acid conjugate.

Removal

Complete elimination of dydrogesterone occurs after 72 hours.

Dosage

Femoston® 1/10 is taken 1 tablet/day (preferably at the same time of day) without interruption, regardless of meals.

In the first 14 days of a 28-day cycle, take 1 tablet daily. white (from half a package with an arrow marked with the number “1”) containing 1 mg of estradiol, and in the remaining 14 days - 1 tablet daily. gray (from half a package with an arrow marked with the number “2”) containing 1 mg of estradiol and 10 mg of dydrogesterone.

Femoston® 2/10 is taken 1 tablet/day (preferably at the same time of day) without interruption, regardless of meals.

In the first 14 days of a 28-day cycle, take 1 tablet daily. pink (from half a package with an arrow marked with the number “1”) containing 2 mg of estradiol, and in the remaining 14 days - 1 tablet daily. light yellow (from half a package with an arrow marked "2") containing 2 mg of estradiol and 10 mg of dydrogesterone.

Patients whose menstruation has not stopped are recommended to begin treatment on the first day of the menstrual cycle. For patients with irregular menstrual cycles, it is advisable to begin treatment after 10-14 days of progestogen monotherapy (“chemical curettage”).

Patients whose last menstruation was observed more than 1 year ago can begin treatment at any time.

Overdose

Symptoms: nausea, vomiting, drowsiness, dizziness.

Treatment: symptomatic therapy.

Drug interactions

The simultaneous use of drugs that are inducers of microsomal liver enzymes (including barbiturates, phenytoin, rifampicin, rifabutin, carbamazepine) may weaken the estrogenic effect of Femoston®.

Ritonavir and nelfinavir, although known as inhibitors of microsomal metabolism, may act as inducers when taken concomitantly with steroid hormones.

Herbal preparations containing St. John's wort can stimulate the exchange of estrogens and progestogens.

The interaction of dydrogesterone, which is part of the drug Femoston®, with other drugs is not known.

Use during pregnancy and lactation

Femoston® is contraindicated for use during pregnancy and lactation.

Side effects

From the reproductive system: possible soreness of the mammary glands, breakthrough bleeding, pain in the pelvic area; sometimes - changes in cervical erosion, changes in secretion, dysmenorrhea; rarely - enlarged mammary glands, premenstrual-like syndrome; in some cases (0.1-1%) - a change in libido.

From the digestive system: possible nausea, flatulence, abdominal pain; sometimes - cholecystitis; rarely (0.01-0.1%) - impaired liver function, in some cases accompanied by asthenia, malaise, jaundice or abdominal pain; very rarely - vomiting.

From the central nervous system: headache, migraine (1-10%); sometimes (0.1-1%) - dizziness, nervousness, depression; very rarely - chorea.

From the cardiovascular system: sometimes - venous thromboembolism; very rarely - myocardial infarction.

From the hematopoietic system: very rarely (<0.01%) - hemolytic anemia.

Dermatological reactions: sometimes - rash, itching; very rarely - chloasma, melasma, erythema multiforme, erythema nodosum, hemorrhagic purpura.

Allergic reactions: sometimes - urticaria; very rarely - angioedema.

Other: changes in body weight; sometimes - vaginal candidiasis, breast carcinoma, increase in the size of leiomyoma; rarely - peripheral edema, intolerance to contact lenses, increased corneal curvature; in some cases (<0.01%) - exacerbation of porphyria.

Storage conditions and periods

List B. The drug should be stored out of the reach of children, at a temperature not exceeding 30°C. Shelf life: 3 years.

Indications

- hormone replacement therapy for disorders caused by natural menopause or menopause resulting from surgical intervention;

— prevention of postmenopausal osteoporosis.

Contraindications

- established or suspected pregnancy;

- lactation period (breastfeeding);

- diagnosed or suspected breast cancer, history of breast cancer;

- diagnosed or suspected estrogen-dependent malignant neoplasms;

- untreated endometrial hyperplasia;

- vaginal bleeding of unknown etiology;

- previous idiopathic or confirmed venous thromboembolism (deep vein thrombosis, pulmonary embolism);

- active or recent arterial thromboembolism;

- acute liver diseases, as well as a history of liver diseases (before normalization of laboratory parameters of liver function);

- porphyria;

- hypersensitivity to the components of the drug.

Use with caution and under the supervision of a physician in patients receiving HRT and having the following diseases and conditions (currently or in history): uterine leiomyoma, endometriosis, thrombosis and their risk factors in history, in the presence of risk factors for estrogen-dependent tumors (for example, breast cancer in the patient's mother), arterial hypertension, benign liver tumor, diabetes mellitus, cholelithiasis, epilepsy, migraine or intense headache, history of endometrial hyperplasia, systemic lupus erythematosus, bronchial asthma, renal failure, otosclerosis.

special instructions

Before prescribing or resuming HRT, it is necessary to collect a complete medical and family history, conduct a general and gynecological examination in order to identify possible contraindications and conditions requiring precautions. During treatment with Femoston®, it is recommended to conduct periodic examinations (the frequency and nature of the examinations are determined individually). In addition, it is advisable to conduct breast examination (including mammography) in accordance with accepted standards, taking into account clinical indications.

Risk factors for thrombosis and thromboembolism while taking HRT are a history of thromboembolic complications, severe forms of obesity (body mass index more than 30 kg/m2) and systemic lupus erythematosus. There is no generally accepted opinion regarding the role of varicose veins in the development of thromboembolism.

The risk of developing deep vein thrombosis of the lower extremities may temporarily increase with prolonged immobilization, major trauma, or surgery. In cases where prolonged immobilization is necessary after surgery, temporary cessation of HRT should be considered 4-6 weeks before surgery.

When deciding on HRT in patients with recurrent deep vein thrombosis or thromboembolism receiving anticoagulant treatment, the benefits and risks of HRT must be carefully assessed.

If thrombosis develops after starting HRT, Femoston® should be discontinued.

The patient should be informed of the need to consult a doctor if the following symptoms occur: painful swelling of the lower extremities, sudden loss of consciousness, dyspnea, blurred vision.

After consultation with the doctor, the patient should stop taking the drug if jaundice appears or deterioration of liver function, a pronounced increase in blood pressure, a newly diagnosed migraine-like attack, pregnancy, or the manifestation of any contraindication.

There is research data demonstrating a slight increase in the incidence of breast cancer detection in women receiving HRT for a long time (more than 10 years). The likelihood of being diagnosed with breast cancer increases with the duration of treatment and returns to normal 5 years after stopping HRT.

Patients who have previously received HRT using only estrogen drugs should be especially carefully examined before starting treatment with Femoston® in order to identify possible endometrial hyperstimulation.

Breakthrough uterine bleeding and mild menstrual-like bleeding may occur in the first months of treatment with the drug. If, despite dose adjustment, such bleeding does not stop, the drug should be discontinued until the cause of the bleeding is determined. If bleeding recurs after a period of amenorrhea or continues after discontinuation of treatment, its etiology should be determined. This may require an endometrial biopsy.

Femoston® is not a contraceptive. Perimenopausal patients are advised to use non-hormonal contraceptives.

The patient should inform the doctor about the medications she is currently taking or was taking before prescribing Femoston®.

The use of estrogens may affect the results of the following laboratory tests: determination of glucose tolerance, study of thyroid and liver functions.

Impact on the ability to drive vehicles and operate machinery

Femoston® does not affect the ability to drive vehicles or operate machinery.

Use for renal impairment

The drug should be taken with caution in case of renal failure.

Use for liver dysfunction

Contraindicated in acute liver diseases, as well as a history of liver diseases (until normalization of laboratory parameters of liver function).

Conditions for dispensing from pharmacies

The drug is available with a prescription.

special instructions

The prescription of Femoston 1/10 is indicated only in the presence of symptoms that have an adverse effect on the quality of life. HRT is recommended until the risk of side effects exceeds the benefits of taking the drug. The limited clinical experience with the drug in women over 65 years of age should be taken into account.

In younger women, the absolute risk from using the drug is much lower than in older women.

To identify possible contraindications, the doctor should prescribe Femoston 1/10 based on a complete medical and family history and after a general gynecological examination of the patient, including mammography. The doctor should inform the woman about those changes in the mammary glands, the appearance of which requires consultation with a doctor. The use of the drug requires mandatory periodic examinations, at least once every 6 months. The doctor determines their nature and frequency individually.

The use of estrogens significantly increases the risk of developing endometrial cancer and hyperplasia, the degree of risk depends on the dose of the drug and the period of HRT. The combined composition of Femoston 1/10, namely cyclic administration of progestogen, reduces the risk of endometrial hyperplasia and cancer caused by estrogens. For timely diagnosis of these pathologies, it is advisable to conduct ultrasound screening, and, if necessary, histological examination. Bloody vaginal discharge, including breakthrough bleeding, may occur during the first months of therapy. If such bleeding occurs at later stages of treatment or occurs after discontinuation of the drug, it is necessary to diagnose their cause. To exclude malignancy, an endometrial biopsy is recommended.

The risk of developing deep vein thrombosis and pulmonary embolism during HRT increases several times, to a greater extent during the first 12 months of drug use. Patients whose first-degree relatives had thromboembolic complications at a young age, or with a history of spontaneous abortion, require a hemostasis study before prescribing the drug. With concomitant anticoagulant therapy, it is necessary to carefully evaluate the feasibility of prescribing Femoston 1/10. For planned surgery followed by long-term immobilization, it is recommended to discontinue HRT 1–1.5 months in advance and resume it only after the patient’s mobility has been completely restored. A woman should be informed about the symptoms of thromboembolism, such as shortness of breath, swelling or tenderness of the lower extremities, sudden chest pain, and the need to immediately consult a doctor if they occur.

The risk of developing breast cancer during combined estrogen-progestogen HRT, which lasts for more than 5 years, increases by 2 times. Breast engorgement caused by the drug may make it difficult to diagnose breast cancer in a timely manner.

There is a risk of developing ovarian cancer, but to a much lesser extent than breast cancer.

Combination therapy with estrogen and progestogen causes an increase in the relative risk of ischemic stroke, which is independent of the patient's age or duration of therapy. It should be borne in mind that the older the patient is at which she begins HRT, the higher the initial risk of ischemic stroke. Femoston 1/10 does not affect the occurrence of hemorrhagic stroke. The risk of developing coronary heart disease increases with age, but this can occur for objective and subjective reasons.

Femoston 1/10 is not a contraceptive.

In patients with impaired renal and cardiac function, their condition may be aggravated by the ability of estrogens to cause fluid retention.

In case of hypertriglyceridemia, HRT in very rare cases can contribute to the development of pancreatitis due to a significant increase in the level of triglyceride concentration in the blood plasma.

The use of the drug does not improve the patient's cognitive functions. When starting HRT after the age of 65, women have an increased risk of developing dementia.

Impact on the ability to drive vehicles and complex mechanisms

Due to the risk of unwanted reactions from the nervous system, it is recommended to exercise caution when operating complex machinery and vehicles.

Why might it be appointed?

As already mentioned, the drug is designed to maintain hormonal balance in women during menopause. However, it is sometimes prescribed to young women who are planning a pregnancy but have difficulty conceiving.

Pros of the appointment

What is the point of prescribing this drug? When taking it, the following effects are noted:

• One of the common reasons for pregnancy failure is that a thick enough layer of endometrium does not form in the uterus, so the fertilized egg is not able to attach to it. Taking the drug helps increase the mucous layer, which increases the chances of pregnancy.
• The second reason for difficulties with conceiving, which can be eliminated by taking the drug, is insufficient production of estrogens.
• In addition, there is reason to believe that taking the drug contributes to the normal course of ovulation.

Advice! However, the ability of the drug to stimulate the onset of ovulation has not been confirmed, and not all doctors believe that it can have a positive effect on a woman’s reproductive system and promote conception.

Cons of appointment

After the list of positive aspects of taking the drug, you may get the impression that Femoston is necessary for couples who cannot conceive. However, some gynecologists believe that taking the drug at the planning stage is not only useless, but even harmful. Therefore, before you start taking the drug, you should get acquainted with its disadvantages. This:

• The hormone content in the product is too high, and excess hormones can negatively affect the development of the embryo after pregnancy.
• The effectiveness of the drug has not been confirmed. Some women were actually able to get pregnant after stopping the drug, but it is impossible to say for sure that it was Femoston that had a positive effect. Moreover, the majority of patients from the control groups did not obtain the desired results after treatment.

• Femoston has many side effects, so most patients feel unwell while taking it.

Advice! The opinions of gynecologists regarding the advisability of prescribing Femoston in case of difficulties with conception differ. Therefore, the patient will need to discuss in detail with her doctor what goals he has in prescribing this drug. In addition, it does not hurt to consult with other specialists. This will help the woman make the right decision.

Drug interactions

When used simultaneously with Femoston 1/10:

• carbamazepine, phenobarbital, phenytoin (anticonvulsants), rifabutin, nevirapine, rifampicin, efavirenz (antimicrobials), St. John's wort, ritonavir, nelfinavir: increase the metabolism of the active components of the drug, which may result in a decrease in its therapeutic effect and a change in the intensity of vaginal bleeding ;
• tacrolimus, cyclosporine, theophylline, fentanyl: can significantly increase their plasma concentration levels.

Femoston reviews 1/10

Reviews of Femoston 1/10 are controversial. Many women give the drug a positive assessment. They indicate its fairly high effectiveness when used to relieve symptoms of menopause. Some of them, comparing mild, infrequent hot flashes during the use of Femoston 1/10 with a state of complete discomfort (severe hot flashes) after discontinuation of the drug, decide to resume HRT. After 5–8 years of use of combined hormonal therapy, rare and minor side effects, improved quality of life, and general well-being are reported.

Negative reviews come from those for whom the drug did not help; they justify their assessment by the lack of the desired clinical result, the development of severe side effects, severe edema, and a significant increase in body weight.

All women consider the disadvantages of Femoston 1/10 to be the high cost of the tablets.

Reviews from doctors, based on the results of clinical studies, indicate the high therapeutic effectiveness of the drug and its good tolerability.

Analogs

The drug has analogues; they can be used if it is impossible to prescribe the original medication.

The most effective substitutes:

• Klimonorm is available in the form of tablets for oral administration, contains 2 hormonal components and can be prescribed to eliminate the symptoms of menopause. The drug is taken in long and short courses, depending on the severity of the manifestations.

• Kliogest also contains 2 hormonal ingredients. The product is available in tablet form, helps eliminate the symptoms of menopause and prevents complications from the reproductive system.

Substitutes are selected only by a doctor after a preliminary examination.